Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

DataMEDS AI, Inc. (MEDS) Guidance & Earnings Results

On 2026-05-19 DataMEDS AI, Inc. raised guidance: "Q2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MEDSDataMEDS AI, Inc.Follow MEDS — free
Medical Distribution · Healthcare
—
Price chart with a free account
Market cap
6.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
18 Nov, in 25 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
19 May 26RaisedQ2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025 $0.486M

DataMEDS AI, Inc. — questions

What guidance did DataMEDS AI, Inc. give?
On 2026-05-19: "Q2-2026 revenue expected $1.775M (projected, $0.86M already recognized through May 18, 2026); sequential growth from Q1-2026 $0.929M and Q4-2025 $0.486M"
When does DataMEDS AI, Inc. report earnings?
DataMEDS AI, Inc.'s next earnings report is expected on 2026-11-18.

Every figure on this page comes from DataMEDS AI, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.